Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sopharma Trading AD's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 38.45.
Sopharma Trading AD's Days Inventory for the
three
months ended in Mar. 2026 was 63.19.
Sopharma Trading AD's Days Payable for the
three
months ended in Mar. 2026 was 49.58.
Therefore, Sopharma Trading AD's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 52.06.
Sopharma Trading AD (XBUL:SFT) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Sopharma Trading AD Cash Conversion Cycle Related Terms
Sopharma Trading AD Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Sopharma Trading AD's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBUL:SFT vs MCK, CAH, COR: Cash Conversion Cycle Comparison
For the Medical Distribution subindustry, Sopharma Trading AD's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma Trading AD Cash Conversion Cycle vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma Trading AD's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Sopharma Trading AD's Cash Conversion Cycle falls into.
Sopharma Trading AD Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Sopharma Trading AD's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma Trading AD (XBUL:SFT) has a Cash Conversion Cycle of 52.06 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Sopharma Trading AD and its competitors.
Is Sopharma Trading AD's Cash Conversion Cycle too high?
Sopharma Trading AD's current Cash Conversion Cycle is 52.06. The Medical Distribution industry median Cash Conversion Cycle is 52.15. Sopharma Trading AD's value of 52.06 is 0.2% below this industry median. Overall, Sopharma Trading AD has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sopharma Trading AD's Cash Conversion Cycle compare to MCK and CAH?
Sopharma Trading AD's Cash Conversion Cycle of 52.06 can be compared against companies in the Medical Distribution industry. The industry median Cash Conversion Cycle is 52.15. Sopharma Trading AD's value of 52.06 is 0.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Distribution company?
The median Cash Conversion Cycle among Medical Distribution companies is 52.15, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma Trading AD's current Cash Conversion Cycle of 52.06 is 0.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Sopharma Trading AD and its competitors. For the Medical Distribution industry, the median Cash Conversion Cycle is 52.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma Trading AD's current Cash Conversion Cycle is 52.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma Trading AD stock overvalued right now?
Based on GuruFocus' analysis, Sopharma Trading AD (XBUL:SFT) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.67, compared to a current price of €2.86 — trading 62.7% below its estimated fair value. The current Cash Conversion Cycle is 52.06 and 0.2% below the Medical Distribution industry median of 52.15. Sopharma Trading AD's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Sopharma Trading AD (XBUL:SFT), the current Cash Conversion Cycle is 52.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma Trading AD (XBUL:SFT) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma Trading AD stock appears to be undervalued.
The current stock price of €2.86 is trading 62.7% below its estimated GF Value™ of €7.67.
GuruFocus considers Sopharma Trading AD to be Significantly Undervalued.
Key valuation signals for XBUL:SFT:
Cash Conversion Cycle: 52.06
GF Value™: €7.67 vs. price of €2.86 (62.7% below fair value)
Industry Position: 0.2% below the Medical Distribution median
No single metric tells the full story. See the XBUL:SFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.
82GF Score
Get the complete analysis for XBUL:SFT
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:SFT has been successfully added to your 
